A second Remicade biosimilar hit the U.S. market to take a larger slash at pricing.

Corning, with input from Pfizer and Merck, intends to build a $500 million plant in the U.S. to produce a new pharma glass.

After an average 44% price cuts, Chinese government will add some blockbuster foreign meds like Celgene's Revlimid to its national insurance scheme.

A whistleblower suit against Gilead is revived, Biocon and Mylan's Herceptin biosim is delayed, and AZ is upping production to meet demands in China.

GlaxoSmithKline is nearing completion of its new manufacturing plant in India that will be able to crank out 8 billion tablets and 1 billion capsules a year.

Gilead hit with revived lawsuit claiming it sourced a key HIV drug ingredient from an unapproved Chinese manufacturer.

Mylan and Biocon have hit a stumbling block that will delay potential approval of their biosimilar of Roche’s Herceptin in Europe.

Celgene buys Beigene’s PD-1 inhibitor, Fosun stumbles over rumors about its chairman, Neopharma expands in Japan and Abu Dhabi, and more.

Pharma Asia